Tempest Therapeutics (TPST) executive compensation, 2025 proxy

Stephen Brady, Chief Executive Officer and President, was paid $1.9M in 2024, down 73% from $7M the year before.

Filed
December 31, 2025
Annual meeting
January 27, 2026
Pay year
2024
Named executives
3
CEO total pay
$1.9M-73% vs prior year
CEO Target Bonus
55%Expressed as percentage of annual base salary
Corporate Goal Attainment
85%Achieved for the 2024 performance bonus

How Brady was paid

$1.9M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary32%Option awards52%Non-equity incentive15%All other compensation1%

Named executive officers

ExecutiveTotal
Stephen BradyChief Executive Officer and President$1,872,299
Samuel WhitingChief Medical Officer$1,062,587
Nicholas MaestasChief Financial Officer$622,095

What changed and why

  • $1.9MStephen Brady received total compensation of $1,872,299 in fiscal 2024, representing a decrease from $7,007,407 in fiscal 2023.
  • $978KOption awards for the CEO decreased to $977,999 in 2024 from $6,084,172 in 2023.
  • 85%Non-equity incentive compensation for the CEO was $280,500 based on 85% corporate goal achievement.
  • Named executive officers transitioned to hourly consulting agreements in June 2025 before being rehired.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.